XM无法为美国居民提供服务。
G
G

GSK


市场新闻

Coca-Cola plans to invest $1 billion in Nigeria operations, presidency says

Coca-Cola plans to invest $1 billion in Nigeria operations, presidency says ABUJA, Sept 19 (Reuters) - Coca-Cola plans to invest $1 billion in its Nigeria operations over the next five years, the country's presidency said after a meeting between President Bola Tinubu and senior executives of the soft drinks maker on Thursday. Tinubu met John Murphy, president and chief financial officer of Coca‑Cola KO.N , Zoran Bogdanovic, CEO of Coca-Cola HBC CCH.L - one of Coca-Cola's many bottlers worldwid
B
G
C

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j
G
P
S

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j
G
P
S

A second Zantac cancer trial ends with hung jury

A second Zantac cancer trial ends with hung jury Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer Ingelheim must pay damages to an Illinois man
G
P
S

GSK settles two California lawsuits related to heartburn drug Zantac

UPDATE 1-GSK settles two California lawsuits related to heartburn drug Zantac Adds background and context Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in either settlement, it said in a statement.
G
P
S

GSK's RSV, Shingles vaccines show on-par immune response in joint trial

UPDATE 1-GSK's RSV, Shingles vaccines show on-par immune response in joint trial Adds details on study in paragraph 2, company's statement in paragraph 4 Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
G

GSK's RSV vaccine meets main goal when co-administered with shingles shot

GSK's RSV vaccine meets main goal when co-administered with shingles shot Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age. The company said co-administration of the vaccines generated an immune response that was at least on-par with separate administration.
G

Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma

BRIEF-Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma Sept 17 (Reuters) - GSK plc GSK.L : GSK PLC - JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA Source text for Eikon: ID:nRSQ4071Ea Further company coverage: GSK.L
G

Iteos falls after mid-stage study results for lung cancer drug

BUZZ-Iteos falls after mid-stage study results for lung cancer drug Updates ** Shares of cancer drug developer Iteos Therapeutics ITOS.O slide 23.6% to $12.76 ** Stock had risen 27 .3% t o $21.26 in premarket trade ** Co says its lung cancer drug belrestotug, in combination with GSK's GSK.L drug dostarlimab, showed higher percentage of reduction or
G

Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone

BUZZ-Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone ** Shares of cancer drug developer Iteos Therapeutics ITOS.O rise 14.7% at $19.16 premarket ** Co says its lung cancer drug, belrestotug, in combination with GSK's GSK.L drug, dostarlimab, showed reduction or disappearance of tumor in 63.3%-76.7% patients, vs
G

Zenas BioPharma shares rise nearly 8% in market debut

UPDATE 2-Zenas BioPharma shares rise nearly 8% in market debut Adds details on U.S. IPO market in paragraph 4-5, details on the company from paragraph 6 onwards Sept 13 (Reuters) - Shares of Bristol-Myers Squibb-backed Zenas BioPharma ZBIO.O rose nearly 8% in their Nasdaq debut on Friday, a sign of recovery for the U.S. initial public offering market in 2024 after two subpar years.
C
G

GSK's Blenrep Receives Breakthrough Therapy Designation In China

BRIEF-GSK's Blenrep Receives Breakthrough Therapy Designation In China Sept 13 (Reuters) - GSK plc GSK.L : GSK PLC - CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP GSK PLC - BLENREP RECEIVES BREAKTHROUGH THERAPY DESIGNATION IN CHINA Source text for Eikon: ID:nRSM0429Ea Further company coverage: GSK.L
G

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial

Antifungal drug developer F2G raises $100 mln to fight 'superbugs', fund late-stage trial By Kashish Tandon Sept 12 (Reuters) - F2G said on Thursday it has raised $100 million from investors including AMR Action Fund, backed by large drugmakers such as Johnson & Johnson and Pfizer, to help it develop treatments for infections caused by drug resistant "superbugs" or microbes.
G
P

UK Stocks-Factors to watch on Sept 12

UPDATE 1-UK Stocks-Factors to watch on Sept 12 Adds news items, updates futures Sept 12 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Thursday, with futures FFIc1 up 1.2%. * GSK: British drugmaker GSK GSK.L announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development.
G
S
D
R

British drugmaker GSK moves mRNA flu vaccine to late-stage trials

UPDATE 1-British drugmaker GSK moves mRNA flu vaccine to late-stage trials Adds details and background throughout Sept 12 (Reuters) - British drugmaker GSK GSK.L announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it would now progress to late-stage clinical development.
G

GSK's mRNA flu vaccine programme to proceed to late-stage trials

GSK's mRNA flu vaccine programme to proceed to late-stage trials Sept 12 (Reuters) - British drugmaker GSK GSK.L on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development. Data showed a vaccine candidate formulation demonstrated positive A and B strain immune responses relative to standard of care in both younger and older adults, GSK said.
G

GSK Announces Positive MRNA Flu Vaccine Phase II Headline Data

BRIEF-GSK Announces Positive MRNA Flu Vaccine Phase II Headline Data Sept 12 (Reuters) - GSK plc GSK.L : POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA VACCINE CANDIDATE SHOWS POSITIVE IMMUNE RESPONSES IN YOUNGER AND OLDER ADULTS DATA SUPPORT PROGRESSION TO PHASE III CLINICAL TRIALS MRNA INFLUENZA VACCINE PROGRAMME TO PROGRESS TO LATE-STAGE DEVEL
G

UK Stocks-Factors to watch on Sept 11

UPDATE 1-UK Stocks-Factors to watch on Sept 11 Adds news items, updates futures Sept 11 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures up 0.15%. * RIGHTMOVE: Britain's largest real estate portal Rightmove RMV.L rejected the 5.6 billion pound ($7.32 billion) cash-and-stock takeover proposal from Australia's REA Group REA.AX , it said, citing that the bid undervalued its prospects.
B
G
N
R
R
A

GSK's experimental herpes vaccine fails to meet main goal in trial

UPDATE 1-GSK's experimental herpes vaccine fails to meet main goal in trial Adds details on the virus and GSK's next moves from paragraph 2 Sept 11 (Reuters) - British drugmaker GSK GSK.L said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
G

GSK Says GSK3943104 HSV Vaccine Candidate Fails To Meet Primary Efficacy Objective

BRIEF-GSK Says GSK3943104 HSV Vaccine Candidate Fails To Meet Primary Efficacy Objective Sept 11 (Reuters) - GSK plc GSK.L : GSK PLC - UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL GSK PLC - COMPLETES PRIMARY DATA ANALYSIS OF PHASE II HSV VACCINE TRIAL GSK PLC - GSK3943104 HSV VACCINE CANDIDATE FAILS TO MEET PRIMARY EFFICACY OBJECTIVE GSK PLC
G



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明